ZYME Zymeworks Inc.companySEC Filings & Insider Trading Activity 2026
Latest Zymeworks Inc. (ZYME) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 2, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Zymeworks Inc. (ZYME) (SEC CIK 1937653), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: biotechnology company developing multifunctional antibody-based therapeutics for cancer, inflammation, and autoimmune diseases
- • New emphasis: commercial launch and milestone revenue focus on Ziihera (zanidatamab-hrii), approved in biliary tract cancer and pending broader regulatory approvals
Risk Factors
- • Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations
- • Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions
Management Discussion & Analysis
- • Revenue $106.0M in 2025, up $29.7M (39%) YoY driven by milestone payments from J&J, BeOne, GSK, Daiichi Sankyo, and BMS
- • Operating expenses: R&D $137.0M (up 2% YoY), G&A $61.5M (flat YoY); R&D increased due to early-stage programs, zanidatamab R&D down 115% to $(1.8)M
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: European Commission granted conditional marketing authorization of Ziihera® in July 2025, contingent on ongoing Phase 3 trial results
- • Material update: FDA accelerated approval of Ziihera® in Nov 2024 requires confirmatory trial; failure may lead to market removal impacting royalties
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Standard Reg FD safe harbor language only — no financial data, operational updates, or material information disclosed in this excerpt
Item 2.03: Creation of a Direct Financial Obligation
- • Item 2.03 covers material financial obligations — key details (amount, rate, maturity, purpose) would determine investor impact
- • Filing text cut off before disclosing any substantive terms of the off-balance sheet arrangement
Item 1.01: Entry into a Material Definitive Agreement
- • $250M upfront from Royalty Pharma via royalty monetization of Ziihera (zanidatamab), structured as a royalty sale + non-recourse term loan at subsidiary level
- • Total repayment obligation: ~$481.3M by Dec 31, 2042 maturity; early repayment by Dec 31, 2033 reduces obligation to $412.5M — implying ~65–93% effective cost of capital
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 2, 2026 — full results in Exhibit 99.1
- • Period covered: three months and full year ended December 31, 2025
Item 7.01: Regulation FD Disclosure
- • Reg FD notice listing official disclosure channels: SEC filings, press releases, website, and social media (X @ZymeworksInc, LinkedIn)
- • Investors should monitor ir.zymeworks.com and social channels — material news may appear there first before broader distribution
Annual Reports Archive10-K
AI-powered analysis of Zymeworks Inc. (ZYME) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Zymeworks Inc. (ZYME) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Zymeworks Inc. (ZYME) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $412.5M | $76.0M | $76.3M | $106.0M |
| Operating Income | $130.5M | -$138.1M | -$137.1M | -$92.5M |
| Net Income | $124.3M | -$118.7M | -$122.7M | -$81.1M |
| Op. Margin | 31.6% | -181.6% | -179.7% | -87.3% |
| Net Margin | 30.1% | -156.1% | -160.8% | -76.6% |
| Balance Sheet | ||||
| Total Assets | $648.7M | $580.9M | $463.1M | $346.5M |
| Equity | $493.0M | $464.8M | $338.8M | $268.5M |
| ROE | 25.2% | -25.5% | -36.2% | -30.2% |
Source: XBRL financial data from Zymeworks Inc. (ZYME) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 1, 2026 | — | — | — |
10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 30, 2025 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Mar 5, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Mar 6, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Mar 7, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — |
Frequently Asked Questions
What are the latest ZYME SEC filings in 2026?
Zymeworks Inc. (ZYME) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ZYME file its most recent 10-K annual report?
Zymeworks Inc. (ZYME) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ZYME 10-Q quarterly reports?
Zymeworks Inc. (ZYME)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every ZYME 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ZYME filed recently?
Zymeworks Inc. (ZYME)'s most recent 8-K was filed on April 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ZYME insider trading activity (Form 4)?
SignalX aggregates every ZYME Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ZYME file with the SEC?
Zymeworks Inc. (ZYME) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ZYME filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Zymeworks Inc. (ZYME).
What is ZYME's SEC CIK number?
Zymeworks Inc. (ZYME)'s SEC CIK (Central Index Key) number is 1937653. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1937653 to look up all ZYME filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ZYME return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Zymeworks Inc. (ZYME) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Zymeworks Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 18+ filings.